Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and ASTX029 in relapsed/refractory AML
NCT06113289Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2024
- Primary completion
- Mar 2025
01
Overview
Phase 2, open-label trial of beroterkib in acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Tolerability at 1 year and Recommended Phase 2 Dose at 1 year. Planned start Feb 2024; status: withdrawn.
02
Drugs
beroterkib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06113289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113289.